Rachna T. Shroff
YOU?
Author Swipe
View article: Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations Open
Supplemental methods, results, tables, and figures
View article: ACR Appropriateness Criteria® Staging and Follow-Up of Primary Liver Cancer
ACR Appropriateness Criteria® Staging and Follow-Up of Primary Liver Cancer Open
View article: Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates Open
Oncogenic KRAS is amongst the key genetic drivers for initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with KrasG12D specific siRNA (iExoKrasG12D) reveal a …
View article: Multi-omic characterization of early-onset esophagogastric cancer
Multi-omic characterization of early-onset esophagogastric cancer Open
Using a large real-world database with matched genomic and transcriptomic data, we characterized clinical and molecular differences between patients with early-onset esophagogastric cancer (EOEGC; 65 years). We analyzed clinicopathologic, …
View article: 344P Patient characteristics, molecular testing, and treatment patterns of patients with cholangiocarcinoma in the United States: Focus on mIDH1 patients
344P Patient characteristics, molecular testing, and treatment patterns of patients with cholangiocarcinoma in the United States: Focus on mIDH1 patients Open
View article: 410P Comprehensive molecular and immunological characterization of CLDN18.2 in esophageal and esophagogastric junction carcinoma (EEJC)
410P Comprehensive molecular and immunological characterization of CLDN18.2 in esophageal and esophagogastric junction carcinoma (EEJC) Open
View article: Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction
Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction Open
Tumor tissues obtained in the clinical setting typically have low purity and display treatment-associated genetic heterogeneity, contributing to variants at low variant allele fractions (VAF). We present a pan-cancer landscape and the ther…
View article: Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel
Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel Open
Biliary tract cancers (BTCs) are a histologically and molecularly diverse group of malignancies arising from the gallbladder and the ductal epithelium of the biliary tree. Intrahepatic cholangiocarcinoma (iCCA) is the second most common pr…
View article: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study Open
PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic…
View article: Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma
Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma Open
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies with a 5-year survival rate of less than 10%. Chemotherapy is the current standard-of-care (SOC) for advanced PDAC; however, treatment resistance driven by a…
View article: Anti–PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time?
Anti–PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time? Open
View article: Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma
Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma Open
Background: Quantitative drug benefit–risk assessment (BRA) helps assess the magnitude of benefit and risk of new cancer therapies. This BRA aimed to summarize the evidence for the benefits and risks of ivosidenib versus placebo for the tr…
View article: Supplementary Table S3 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Supplementary Table S3 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma Open
Supplementary Table S3: Comparison of MPAS gene expression between KRAS mutational subgroups. Median values represent transcript per million (TPM). Only genes with trending or significant differences between subgroups are shown. Bold numbe…
View article: Supplementary Table S2 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Supplementary Table S2 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma Open
Supplementary Table S2: Comparison of TP53 and CDKN2A genomic alterations between KRAS G12R and G12D subgroups.
View article: Supplementary Table S4 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Supplementary Table S4 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma Open
Supplementary Table S4: Comparison of cytokine gene expression between KRAS mutational subgroups. Median values represent transcript per million (TPM). Only genes with trending or significant differences between subgroups are shown. Bold n…
View article: Supplementary Table S5 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Supplementary Table S5 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma Open
Supplementary Table S5: GSEA analysis comparing enrichment of gene expression pathways in G12R compared to G12D cohorts. Negative enrichment score (es) indicates lower enrichment in G12R.
View article: Data from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Data from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma Open
Purpose:Oncogenic mutations in KRAS have been identified in >85% of pancreatic ductal adenocarcinoma (PDAC) cases, with G12D, G12V, and G12R being the most frequent variants. Using large clinical and genomic databases, this study ch…
View article: Supplementary Table S1 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Supplementary Table S1 from Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma Open
Supplementary Table S1: Comparison of genomic alterations between KRAS G12R and G12D subgroups related to the PI3K/AKT/MTOR pathway.
View article: KRAS<sup>G12D</sup>-Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients
KRAS<sup>G12D</sup>-Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients Open
Oncogenic KRAS drives initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with Kras G12D specific siRNA (iExoKras G12D ) reveal impressive biodistribution in pancreas with negligibl…
View article: Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database
Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database Open
Background Previous research demonstrates longer survival for patients with lung-only metastatic pancreatic adenocarcinoma (mPDAC) compared to liver-only mPDAC. The objective of this study is to understand the survival differences, impact …
View article: Supplementary Table S5 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Supplementary Table S5 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies Open
Supplementary Table S5. Measurement of IL18 in peripheral blood during cycle 1 of treatment with cinrebafusp alfa.
View article: Supplementary Figure S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Supplementary Figure S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies Open
Supplementary Figure S2. Analysis of CD8 Ki67+ T cells in paired tumor biopsies across different dose cohorts.
View article: Supplementary Figure S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Supplementary Figure S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies Open
Supplementary Figure S1. Mean concentration of s4-1BB over time during treatment.
View article: Supplementary Table S4 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Supplementary Table S4 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies Open
Supplementary Table S4. Measurement of IP10 in peripheral blood during cycle 1 of treatment with cinrebafusp alfa.
View article: Supplementary Table S3 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Supplementary Table S3 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies Open
Supplementary Table S3. Measurement of IFNG in peripheral blood during cycle 1 with cinrebafusp alfa.
View article: Supplementary Table S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Supplementary Table S2 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies Open
Supplementary Table S2. Representativeness of Study Participants.
View article: Data from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Data from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies Open
Purpose:4-1BB (CD137) is a costimulatory immune receptor expressed on activated T cells, activated B cells, NK cells, and tumor-infiltrating lymphocytes, making it a promising target for cancer immunotherapy. Cinrebafusp alfa, a monoclonal…
View article: Supplementary Table S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies
Supplementary Table S1 from A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies Open
Supplementary Table S1. Disposition of patient enrolled on study.
View article: Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma
Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma Open
Purpose: Oncogenic mutations in KRAS have been identified in >85% of pancreatic ductal adenocarcinoma (PDAC) cases, with G12D, G12V, and G12R being the most frequent variants. Using large clinical and genomic databases, this study chara…
View article: SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Open
PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs). METH…